Imdatifan clinical trials
Also written NKT2152.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses imdatifan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- NKT2152
- 2
Studies by the year they started
3 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
NiKang Therapeutics, Inc. (2) · Hoffmann-La Roche (1)
Often tested with
Tested in the same studies.
Bevacizumab (1) · Tiragolumab (1) · Tocilizumab (1) · Amezalpat (1) · Tobemstomig (1) · Muzastotug (1) · Anti-LILRB2 Monoclonal Antibody IO-108 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test imdatifan.
Studies
Open first, then newest update. How each study uses imdatifan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)Active, not recruitingPhase 1/2Hoffmann-La RocheNCT04524871Written as NKT2152
- Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)TerminatedPhase 2NiKang Therapeutics, Inc.NCT05935748Written as NKT2152
- A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell CarcinomaTerminatedPhase 1/2NiKang Therapeutics, Inc.NCT05119335Written as Oral NKT2152
Codes
What other systems call imdatifan · ClinicalTrials.gg INT016118
- UNII (FDA) BL9SLT39J6IMDATIFANOne source FDA
- NCI Thesaurus C203107ImdatifanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | BL9SLT39J6 | IMDATIFAN | One source FDA |
| NCI Thesaurus | C203107 | Imdatifan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.